Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316

K. Cunningham, Coleen; Chaix, Marie‐Laure; Rekacewicz, Claire; Britto, Paula; Rouzioux, Christine; D. Gelber, Richard; Dorenbaum, Alejandro; François Delfraissy, Jean; Bazin, Brigitte; Mofenson, Lynne; L. Sullivan, John

doi:10.1086/341300

Public

Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316

Published in The Journal of Infectious Diseases • Jul 15, 2002

Authors:

Coleen K. Cunningham

Marie‐Laure Chaix

Claire Rekacewicz

Abstract

Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral th...

Subject

Nevirapine

Medicine

Viral load

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!